Research & Development
Non Small Cell Lung Cancer: Page 4
Lucence offers expanded cfRNA version LiquidHallmark
Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."
January 9, 2022
Quest offers Biocept's liquid biopsy test
Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.
December 1, 2021
FDA expands use of Qiagen lung cancer mutation test
Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.
June 1, 2021
Falling lung cancer rates drive cancer decline in U.S. over past 2 decades
The report found that in 2020, the cancer death rate was down by 31% compared with 1991, including a 2.4% decrease between 2017 and 2018, the ACS reported. The findings are in line with prior reports showing cancer death rates overall dropping in recent years.
January 11, 2021
FDA clears Foundation Medicine's liquid biopsy test
FoundationOne Liquid CDx can be used as a companion diagnostic for four cancer therapies, including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor for metastatic prostate cancer patients with BRCA1/2 mutations, and three epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer patients.
August 26, 2020
Cancer research groups partner for liquid biopsy trial
In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.
July 29, 2020
Insurance coverage of liquid biopsies for cancer surges
The study evaluated private insurance and Medicare coverage trends for tests that identify circulating tumor DNA (ctDNA), cell-free DNA fragments shed by tumors that contain information about the tumor's genetic properties. Clinicians can use the ctDNA data from liquid biopsies to make treatment decisions.
July 9, 2020
Seoul researchers tout Guardant360 clinical results
A team from Samsung Medical Center in Seoul found that the test offers "useful prognostic information beyond actionable biomarkers" for this patient population, Guardant said in a statement.
May 31, 2020
FDA approves Agilent assay for lung cancer
The test, called PD-L1 IHC 28-8 pharmDx, will help physicians identify patients with metastatic NSCLC who qualify for treatment with a dual immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both of which are manufactured by Bristol Myers Squibb.
May 17, 2020
Qiagen, NuProbe partner on next-generation sequencing liquid biopsy
The companies plan to integrate NuProbe's blocker displacement amplification technology with Qiagen's single primer extension technology to analyze DNA mutations with very low variant allele fractions and support noninvasive cancer genomic profiling. They also aim to develop NGS liquid biopsy oncology panels capable of achieving limit-of-detection standards more cost-effectively than other existing technologies.
March 16, 2020
BioMarker Strategies advances immunotherapy test through SBIR grant
The contract runs for two years and covers use of the test for predicting response to treatments given alone or in combination to patients with non-small cell lung cancer (NSCLC). This represents the second phase of immunotherapy response test development for the NCI; in the first phase, BioMarker Strategies established proof of concept. Immunotherapies have revolutionized the treatment of several cancer types, but there is a strong need for better ways of identifying patients who benefit, as the objective response rates for PD-1/PD-L1 inhibitors are low, ranging from 10% to 30%.
January 6, 2020
FDA clears FoundationOne CDx for Piqray in breast cancer
Piqray was approved by the FDA in May for second-line treatment in combination with fulvestrant for postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer.
December 3, 2019
Page 4 of 5